標(biāo)題: Titlebook: Clinical Use of Calcium Channel Antagonist Drugs; Lionel H. Opie,William A. Coetzee Book 1989 Kluwer Academic Publishers, Boston 1989 angi [打印本頁(yè)] 作者: 二足動(dòng)物 時(shí)間: 2025-3-21 18:12
書(shū)目名稱(chēng)Clinical Use of Calcium Channel Antagonist Drugs影響因子(影響力)
書(shū)目名稱(chēng)Clinical Use of Calcium Channel Antagonist Drugs影響因子(影響力)學(xué)科排名
書(shū)目名稱(chēng)Clinical Use of Calcium Channel Antagonist Drugs網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱(chēng)Clinical Use of Calcium Channel Antagonist Drugs網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱(chēng)Clinical Use of Calcium Channel Antagonist Drugs被引頻次
書(shū)目名稱(chēng)Clinical Use of Calcium Channel Antagonist Drugs被引頻次學(xué)科排名
書(shū)目名稱(chēng)Clinical Use of Calcium Channel Antagonist Drugs年度引用
書(shū)目名稱(chēng)Clinical Use of Calcium Channel Antagonist Drugs年度引用學(xué)科排名
書(shū)目名稱(chēng)Clinical Use of Calcium Channel Antagonist Drugs讀者反饋
書(shū)目名稱(chēng)Clinical Use of Calcium Channel Antagonist Drugs讀者反饋學(xué)科排名
作者: Ferritin 時(shí)間: 2025-3-21 23:27 作者: 繁忙 時(shí)間: 2025-3-22 03:31
https://doi.org/10.1007/978-1-4842-4810-2s of existing agents include slow-release formulations of nifedipine, verapamil, and diltiazem. From all these agents will be selected those that are longer-acting and provide higher vascular selectivity.作者: candle 時(shí)間: 2025-3-22 08:35 作者: 曲解 時(shí)間: 2025-3-22 10:03 作者: 颶風(fēng) 時(shí)間: 2025-3-22 13:18
Clinical Pharmacokinetics of First and Second-Generation Agents,lcium antagonists. There are also other potential drug interactions of a kinetic or dynamic nature that may arise. In general, renal disease has little effect on the pharmacokinetics of calcium antagonists.作者: 颶風(fēng) 時(shí)間: 2025-3-22 17:46 作者: 痛苦一下 時(shí)間: 2025-3-22 21:36 作者: troponins 時(shí)間: 2025-3-23 01:48 作者: 頌揚(yáng)國(guó)家 時(shí)間: 2025-3-23 05:53
Use and Comparative Efficacy in Hypertension and Supraventricular Arrhythmias. Minor Indications,eft ventricular hypertrophy or renal insufficiency. However, the goal blood pressure may not be reached during monotherapy so that drug combinations may be required. Further indications for these compounds are as follows. Verapamil and diltiazem are frequently used in supraventricular tachycardias i作者: 光滑 時(shí)間: 2025-3-23 11:01
Side Effects and Contraindications Drug Interactions and Combinations,re unless caused by hypertensive heart disease. Drug interactions of calcium antagonists occur with other cardiovascular agents such as α-adrenergic blockers, β-adrenergic blockers, digox in, quinidine, and disopyramide. The most marked interaction with digoxin is that with verapamil, which may rais作者: LASH 時(shí)間: 2025-3-23 15:56
Epilogue. Where Do We Go from Here?,tihypertensive properties established. Yet when one considers that the main action of all calcium antagonists is inhibition of vascular smooth muscle contraction, it is surprising that the antihypertensive effect has been so well disguised for so long. Probably this delay has been in part because th作者: 昏睡中 時(shí)間: 2025-3-23 20:44
Book 1989n and com- pare with the three first-liners? When the gloss is taken away from the advertisements, what is really left? The strong clinical bias of the present book should be complimented by further reading of books slanted towards fundamentals. One of the most important and recent of these is that 作者: URN 時(shí)間: 2025-3-24 00:00 作者: anthropologist 時(shí)間: 2025-3-24 05:53
https://doi.org/10.1007/978-3-319-02192-8to other ions and in their sensitivity to membrane potential and to drugs..It is not quite clear how the calcium current is changed during myocardial ischemia. Factors that may reduce the calcium current during ischemia are the increased extracellular potassium concentration, metabolic inhibition an作者: 嚴(yán)厲批評(píng) 時(shí)間: 2025-3-24 10:32
https://doi.org/10.1007/978-3-319-02192-8ctivity, generally held to be a desirable property because the negative inotropic effect is usually a liability. The general clinical impression that nifedipine is the agent most active in vascular tissue in relation to the myocardial effect is supported by data on the relative potencies of these th作者: handle 時(shí)間: 2025-3-24 10:40 作者: 宏偉 時(shí)間: 2025-3-24 16:00 作者: 裝入膠囊 時(shí)間: 2025-3-24 19:32 作者: TRUST 時(shí)間: 2025-3-25 00:25 作者: Benzodiazepines 時(shí)間: 2025-3-25 04:43
Channel-Mediated Calcium Current in the Heart,isms, including several exhange mechanisms and pumps. This review concentrates on the influx of calcium ions through channels in the sarcolemma, resulting in an electric current flow. The calcium current plays an important role in the maintenance of the action potential duration, in the generation o作者: Lipoprotein 時(shí)間: 2025-3-25 09:08 作者: perjury 時(shí)間: 2025-3-25 13:19
Use and Comparative Properties of the Three Prototypical Calcium Antagonists in Ischemic Heart Disese syndromes. In effort angina, verapamil in a dose of 360–480 mg daily is better than propranolol in standard doses. Although nifedipine is highly effective against vasospastic angina, its use in threatened myocardial infarction or severe unstable angina is not supported by recent studies, unless c作者: 盡管 時(shí)間: 2025-3-25 19:47
Use and Comparative Efficacy in Hypertension and Supraventricular Arrhythmias. Minor Indications,onses of the baroreflexes and the renin-angiotensin-aldosterone system. In severe hypertension, the concept that calcium overload of the vascular myocyte could precipitate or aggravate peripheral vasoconstriction provides a logical basis for the use of these agents as first choice therapy; nifedipin作者: FACT 時(shí)間: 2025-3-25 21:22
Side Effects and Contraindications Drug Interactions and Combinations,effects. Almost all side effects are dose related. Minor side effects include those caused by vasodilation (flushing and headaches), constipation (verapamil), and ankle edema. Serious side effects are rare and result from improper use of these agents, as when intravenous verapamil (or diltiazem) is 作者: CAB 時(shí)間: 2025-3-26 03:45
Second-Generation Agents,ine. Verapamil-like agents include tiapamil, gallopamil, and anipamil. Among the diphenylalkylamines, bepridil is of special interest. New preparations of existing agents include slow-release formulations of nifedipine, verapamil, and diltiazem. From all these agents will be selected those that are 作者: 充足 時(shí)間: 2025-3-26 04:20 作者: tic-douloureux 時(shí)間: 2025-3-26 09:18 作者: 陳舊 時(shí)間: 2025-3-26 13:01 作者: ureter 時(shí)間: 2025-3-26 18:27
https://doi.org/10.1007/978-3-319-02192-8ar importance are verapamil, nifedipine, and diltiazem, in historical order of appearance. These agents all have different molecular structures and bind separately with receptor sites located in or near the calcium channel, at molecular sites still to be fully identified. There are probably three di作者: Mystic 時(shí)間: 2025-3-27 00:59
https://doi.org/10.1007/978-3-319-02192-8se syndromes. In effort angina, verapamil in a dose of 360–480 mg daily is better than propranolol in standard doses. Although nifedipine is highly effective against vasospastic angina, its use in threatened myocardial infarction or severe unstable angina is not supported by recent studies, unless c作者: nutrients 時(shí)間: 2025-3-27 02:21 作者: EXUDE 時(shí)間: 2025-3-27 08:38
Scala Programming for Big Data Analytics effects. Almost all side effects are dose related. Minor side effects include those caused by vasodilation (flushing and headaches), constipation (verapamil), and ankle edema. Serious side effects are rare and result from improper use of these agents, as when intravenous verapamil (or diltiazem) is 作者: 尖酸一點(diǎn) 時(shí)間: 2025-3-27 11:56 作者: CODA 時(shí)間: 2025-3-27 14:29 作者: patriot 時(shí)間: 2025-3-27 21:05
https://doi.org/10.1007/978-1-4842-3108-1and reported in an article rejected in disbelief by a premier American journal, did any of these agents come to be widely used. Soon thereafter followed the 1st International Nifedipine ‘Adalat’ Symposium in Tokyo in 1973, the publication from which eventually persuaded clinicians to take seriously 作者: 邊緣帶來(lái)墨水 時(shí)間: 2025-3-28 00:35
http://image.papertrans.cn/c/image/228284.jpg作者: 發(fā)怨言 時(shí)間: 2025-3-28 04:40 作者: Spongy-Bone 時(shí)間: 2025-3-28 09:12
978-1-4612-8208-2Kluwer Academic Publishers, Boston 1989作者: Iatrogenic 時(shí)間: 2025-3-28 10:37
https://doi.org/10.1007/978-1-4842-3108-1This part summarizes in tabular form the information already presented in detail in the previous six parts.作者: Inflammation 時(shí)間: 2025-3-28 14:41 作者: predict 時(shí)間: 2025-3-28 20:43
